Published in final edited form as:

J Agric Food Chem. 2013 November 6; 61(44): . doi:10.1021/jf4019849.

Fatty Acids with *in vitro* Binding Affinity for Human Opioid Receptors from the Fungus *Emericella nidulans*

Amer H. Tarawneh[†], Francisco León[†], Mohamed M. Radwan[‡], Xiaoning Wang[†], Olivia R. Dale[†], Afeef A. Husni[†], Luiz H. Rosa[§], and Stephen J. Cutler^{†,‡,*}

[†]Department of Medicinal Chemistry, The University of Mississippi, University, MS 38677, USA

[‡]National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA

[§]Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Abstract

Bioassay-guided fractionation of the EtOAc extracts of the epiphytic fungus *Emericella nidulans* resulted in the isolation of a mixture of two fatty acids. This mixture showed 98% binding affinity to human δ opioid receptor. These two fatty acids were identified as palmitic (PAM), **1**, and linoleic acids (LNA), **2**, by 1D NMR as well as by GC/MS analysis, after their methylation. We found that different ratio mixtures of **1** and **2** showed variations in selective binding activities to human δ opioid receptors. Five more fatty acids, arachidonic acid (ARA), **3**, *cis*, 4,7,10,13,16,19-docosahexanoic acid (DHA), **4**, *cis*, 5,8,11,14,17,-eicosapentaenoic acid (EPA), **5**, linolenic acid (ALA), **6**, and γ -linolenic acid (GLA), **7**, were evaluated for their binding affinity for opioid receptors. ARA, **3**, displayed affinity to δ and μ human opioid receptors with 68% and 80%, respectively. GLA, **7**, showed selective binding affinity to μ receptor with a value of 55%. These findings provide fascinating insight into the use of foods with high concentrations of fatty acids.

Keywords

Emericella nidulans; opioid receptors; fatty acids; palmitic acid; linoleic acid

Introduction

Fatty acids play important roles in our daily life; they serve as components of biological membranes, they aid cell membrane development, strength, and function, they are essential for organs and tissue, and they are used for metabolic fuel. They are also endogenous ligands for nuclear receptors that initiate transcription of multiple genes, for instance peroxisome proliferator-activated (PPARs) receptors.¹ In recent years, natural lipids have been identified as endogenous leads for the central cannabinoid receptors, which belong to the family of G protein coupled (GPCRs) receptors and are associated with many processes including pain, neurodegeneration, metabolic regulation, anxiety and immune function.²

Some polyunsaturated fatty acids (PUFA) like docosahexaenoic acid (DHA) and arachidonic acid (ARA) play critical roles in neural development as structural components of neuronal membranes and by acting as precursors for lipid derived messengers.³ Recent

*Corresponding author: Phone: 1-662-915-7101; Fax: 1-662-915-5638; cutler@olemiss.edu.

studies show that the ratio of omega-3 and omega-6 PUFA is important in the control of many brain functions.⁴

Opioid receptors are members of the superfamily of G protein-coupled receptors (GPCRs); the three major types are μ (mu), δ (delta) and κ (kappa).⁵ The three receptors mediate pain inhibition and are found throughout the nervous system including in somatic and visceral sensory neurons, spinal cord projection and interneurons, and the midbrain and cortex. Recently, opioid receptors have been identified on peripheral processes of sensory neurons.⁶ In general, interaction with μ opioid receptors produces analgesia, respiratory depression, decrease gastric motility, emesis and tolerance, while interaction with κ agonists produce analgesia, diuresis, sedation and dysphoria. The δ receptor antagonists have shown clinical potential as immunosuppressant's, for treatment of cocaine abuse and in the treatment of brain disorders.⁷

During the course of examining fungi for biologically active natural products,⁸ we assessed the EtOAc extract from the fungus *Emericella nidulans* in a high-throughput screen employing a receptor binding assay for specific opioid receptors. The bioassay-guided fractionation and isolation resulted in the identification of a mixture of two fatty acids possessing good opioid receptor binding affinity.

Materials and Methods

General Experimental Procedure

The IR spectra were measured on a Bruker Tenso 27 instrument. ¹H and ¹³C NMR spectra were obtained on a Varian 400 spectrometer with standard pulse sequences, operating at 400 MHz in ¹H and 100 MHz in ¹³C. The chemical shift values were reported in parts per million units (ppm) from trimethylsilane (TMS) using CDCl₃ as solvent. Column chromatographic separation was performed on silica gel 60 (0.04–0.063 mm). TLC was performed on precoated TLC plates with silica gel 60 F254 (0.25 mm, EMD). The mobile phase used for TLC analyses was EtOAc:hexane (20:80). GC/MS analyses were carried out on a ThermoQuest Trace 2000 GC, equipped with a single split/splitless capillary injector, a ThermoQuest AS2000 autosampler and a Phenomenex ZB-5 column (30 m × 0.25 mm × 0.25 μ m), interfaced to a ThermoQuest-Finnigan Trace MS quadrupole ion trap detector. The injector temperature was 250 °C and 1 μ L injections were performed in splitless mode, with the splitless time set at 60 s, the split flow set at 50 mL/min and the septum purge valve set to close 60 s after the injection occurred. The oven temperature was raised from 70 to 270 °C (hold 20 min) at a rate of 5 °C/min, for a total run time of 60 min; the transfer line temperature was 250 °C. Helium was used as the carrier gas at a constant pressure of 20 psi. The mass spectrometer was operated in the electron impact mode (EI+) and scanned from 40 to 800 amu at 1 scan/s, with an ionizing voltage of 70 eV and an emission current of 350 μ A. Data was recorded using an IBM Netfinity 3000 Workstation with Microsoft Windows NT 4.0 operating system (Build 1381, Service pack 6) and Xcalibur data acquisition and analysis software (Version 1.2). The NIST Mass Spectral Search Program (Version 1.7, Build 11/05/1999) for the NIST/EPA/NIH Mass Spectral Library was employed to assist in the identification of the fatty acids. Standards of arachidonic, *cis*, 4,7,10,13,16,19-docosahexanoic, *cis*, 5,8,11,14,17, -eicosapentaenoic, linolenic, γ -linolenic, palmitic and linoleic acids were purchased from Sigma Chemical Co. (Germany).

Identification of Fungal Material

The strain of *Emericella nidulans* (Eidam) Vuillemin used in this study was collected from a piece of orange peel in Tifton, Georgia in 1978 and the membership of the isolate in this species was confirmed through phylogenetic, physiological and morphological analysis. A

voucher specimen (UM-032009) has been deposited in the culture collection of the Medicinal Chemistry Department, University of Mississippi.

Phylogenetic analysis

Genomic DNA from the fungal strain UK-101 was extracted with DNeasy Plant Mini Kit (Qiagen Inc., Valencia, CA) and used as a template in PCR amplifications. The ITS1-5.8S-ITS2 genomic region (ITS) was amplified from genomic DNA using the forward primer ITS1 (5'-TCCGTAGGTGAACCTGCGG-3') and the reverse primer ITS4 (5'-TCCTCCGCTTATTGATATGC-3').⁹ PCR amplifications were carried out in 50 μ L reaction mixture containing 1 $\times$ PCR reaction buffer, 0.2 mM dNTP mixture, 0.2 μ M of each forward and reverse primers, 1.5 mM MgSO₄ and 2 U of Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA). The PCR program consisted of one initial denaturation step at 94 °C for 3 min followed by 40 cycles at 94 °C for 30 sec, 50 °C for 30 sec, 72 °C for 1:30 min, with a final extension at 72 °C for 7 min. PCR was performed in an M&J Research Gradient Cycler PTC-225. After amplification, an aliquot was analyzed by electrophoresis on a 1% TAE agarose gel, visualized under UV light and PCR products were compared to the molecular size standard 1kb plus DNA ladder (Invitrogen, Carlsbad, CA). Successfully amplified PCR products were extracted using MinElute PCR Purification Kit (Invitrogen, Carlsbad, CA) and sequenced on an automated DNA Sequencer (model ABI 3730XL; Applied Biosystems, Foster City, CA). Consensus sequence data of the fungus was submitted to the GenBank database under the strain UK-101. The sequence obtained was submitted to phylogenetic inferences, which were estimated using MEGA Version 5.0.¹⁰ The maximum composite likelihood model was used to estimate evolutionary distance with bootstrap values calculated from 1,000 replicate runs. The sequence of the type fungal species and some reference sequences deposited in GenBank were added to phylogenetic analysis accuracy. Information about the fungal taxonomic hierarchical levels follows the databases MycoBank (www.mycobank.org) and Index Fungorum (www.indexfungorum.org).

Physiological and Morphological Analysis

The physiological and morphological characteristics of the strain UK-101 were observed on CYA media (Difco, USA). The colony diameter was measured on media, which was inoculated in three-point cultures and incubated for 7 days at 25 $\pm$ 2 °C under cool-white fluorescent lights (55 $\pm$ 5 μ mol/m²/s) with a 12 h photoperiod to sporulation. A duplicate set of CYA plates was incubated in the dark at 25 $\pm$ 2 °C to microscopic parameters determination using slide cultures mounted in methyl blue in polyvinyl-lactophenol.

Fungal Culture

Emericella nidulans was grown on potato-dextrose agar (PDA) at 24 °C until discrete fungal colonies appeared. Samples were taken from colonies and kept on PDA slants in test tubes at 24 °C, then placed in a 4 °C refrigerator until needed. The fungus was inoculated in 50 mL of potato-dextrose broth and kept for two weeks in stationary phase at 24 °C; then the fungus was seeded onto a medium in each flask consisting of 100 g of shredded wheat, 200 mL of low-pH Oxoid mycological broth, 2% yeast extract, and 20% sucrose in 2.0 L Fernbach flasks (10 flasks) followed by incubation for 22 days at 24 °C.

Extraction and Isolation

Following incubation, 500 mL of acetone were added to each flask, and the mycelia and the substrate were homogenized (Super Dispex, Tekmark Co., SD-45). The suspension was filtered and then the filtrate was concentrated under vacuum at 40 °C. The residue was mixed with H₂O (200 mL), then extracted with EtOAc (500 mL $\times$ 3). The EtOAc extracts

were combined, dried over anhydrous Na_2SO_4 , and concentrated under vacuum. The EtOAc extract (23.0 g) was chromatographed on Si gel VLC with stepwise fractions from hexanes to methanol, yielding eight fractions (100% hexane, 75% hexane in EtOAc, 50% hexane in EtOAc, 25% hexane in EtOAc, 100% EtOAc, 75% EtOAc in MeOH, 50% EtOAc in MeOH and 100% MeOH). The second fraction (75% hexane in EtOAc, 3.46 g) showed strong binding affinities for opioid receptors. This fraction was chromatographed on a silica gel column (2.0×40 cm) eluted with hexane-EtOAc gradient to yield eight subfractions. All fractions were submitted for opioid binding activity. Subfraction 4 (707 mg) displayed selective and strong binding affinity (98%) to δ opioid receptor. GC/MS and TLC analysis indicated that subfraction 4 was a mixture of palmitic and linoleic acids (13:87).

Fatty Acids Methylation

Subfraction 4 (2 mg) dissolved separately in 0.5 mL dry ether (in a GC vial) and freshly prepared diazomethane solution was added (6 drops) twice (until effervescence ceased). The ethereal reaction mixture was evaporated in the GC vial and the residue was dissolved in 0.8 mL dry ether and the vial was capped and subjected to GC/MS.

Cell Culture

CHO-K1 cells stably transfected with opioid receptor subtypes μ , δ , and κ , were used to perform the opioid receptor binding assays. These cells were maintained at 37°C and 5% CO_2 in a Dulbecco's Modified Eagle Medium (DMEM) nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal bovine serum, penicillin–streptomycin, and either G418 or hygromycin B antibiotic solutions. Membranes for the radio-ligand binding assays were prepared by scraping the cells in a 50 mM Tris-HCl buffer, followed by homogenization, sonication and centrifugation for 40 min at 13650 rpm at 4°C . These were kept at -80°C until used for bioassays. Protein concentration was determined via Bio-Rad Protein Assay.¹¹

Radioligand Binding for Opioid Receptor Subtypes

Saturation experiments determine the receptor number and radioligand affinity for the membrane. Opioid binding assays were performed under the following conditions: $10\ \mu\text{M}$ of each mixture was incubated with [^3H]-DAMGO (μ), [^3H]-U-69,593 (κ), or [^3H]-enkephalin (δ) for 60 minutes in a 96-well plate. Percent binding was calculated as the average of the triplicate tested at $10\ \mu\text{M}$. Each sample concentration point of the compounds tested in dose response was in triplicate, and each compound showing activity was tested at least three times. The reaction was terminated via rapid vacuum filtration through GF/B filters presoaked with 0.3% bovine serum albumin (BSA) using a Perkin Elmer 96-well Unifilter followed by 10 washes with 50 mM Tris-HCl. Plates were read using a Perkin Elmer Topcount. Total binding was defined as binding in the presence of 1.0% DMSO. Nonspecific binding was the binding observed in the presence of $10\ \mu\text{M}$ DAMGO (μ), nor-binaltorphimine (κ), or DPDPE (δ). Specific binding was defined as the difference between total and nonspecific binding. Percent binding was calculated using the following formula:

$$100 - (\text{binding of compound} - \text{nonspecific bindings}) * 100 / \text{specific binding}.$$

K_i and IC_{50} values were calculated using Graph-Pad Prism 5, each point on the graph is representative of $n=3$.

The binding Assays of the fatty acids were performed in two independent experiments, and the results are similar for both studies (only the data for first experiment are shown).

Results and Discussion

Identification of the Strain UK-101

The sequence of the fungal strain UK-101 displayed 99% of identity with different sequences of *Aspergillus* and *Emericella* species deposited in GenBank database. However, according to Gazis *et al.* and Ko *et al.*,^{12,13} sequencing of the ITS region may fail to recognize some *Ascomycota* taxa and for this reason there are several erroneous fungal sequences deposited in GenBank. To increase the taxonomy accuracy and avoid mistakes on the phylogenetic inferences, the ITS1-5.8S-ITS2 nuclear ribosomal gene sequence of the strain UK-101 was compared with sequence of type species of *Aspergillus* and *Emericella*. The nucleotides difference among the strain UK-101 and the sequence of the type species *Emericella nidulans* NRRL 2395 (AY373888) was of the 10 nucleotide (0.2%). In addition, the strain UK-101 displayed in CYA after 7 days at 25 ± 2 °C, under cool-white fluorescent lights (55 ± 5 $\mu\text{mol}/\text{m}^2/\text{s}$) with a 12 h photoperiod, colonies spreading rapidly, velvety, in green shades with a whitish margin; anamorph state dominating, with scattered green ascomata within and upon the conidial layer. Ascomata globose, green, solitary, 200 μm diam., maturing in 10 days, soft-walled. Asci with 10 μm diam. Ascospores lenticular, 4.0×3.0 μm , green, maturing within 7 days, smooth-walled. Using physiological, morphological characteristics and molecular techniques, the strain UK-101 was identified as *Emericella nidulans* (Eidam) Vuillemin (Figure 1).

Identification of Fatty Acids

Preliminary evaluation by ^1H NMR spectrum showed characteristic signals of olefinic protons (5.2– 5.4 ppm), protons attached to the *bis*-allylic carbons (2.7 ppm), protons attached to the allylic carbons (2.0 ppm), protons α to an acid group (2.3 ppm) and the terminal methyl group protons (0.88 ppm). Furthermore, the methylene (CH_2)_n protons at 1.2–1.4 ppm in its ^1H NMR, as well as, carbonyl signals at 180.3 ppm in its ^{13}C NMR are indicative of a fatty acid mixture. To determine which acids were present in the active fraction and their ratio, the fraction was subjected to GC-MS and two major compounds were observed with retention times of 15 and 16 min peaks corresponding to molecular ions at m/z 256 and 280, which correspond to palmitic acid and linoleic acid, respectively in a mixture of 13:87 ratio. To confirm the identification of the fatty acids, the methyl ester of the mixture was synthesized and molecular ions at m/z 270 and 294 were observed in the GC/MS corresponding to the palmitic and linoleic methyl esters, respectively. Furthermore, the mixture was co-injected with standards of palmitic and linoleic acids, which confirmed the fatty acids produced by UK-101.

Opioid Activity of Fatty Acid

The active fraction proved to be (PAM) and (LNA) with 13:87 ratio. This mixture showed 98% binding affinity to human δ opioid receptors with IC_{50} and K_i values of 1.6 and 0.8 μM , respectively (Table 1), with no relevant binding affinity toward κ or μ opioid receptors. In order to investigate the fatty acids concentration ratio effect on the binding affinity to δ opioid receptors, eleven different mixtures of (PAM) and (LNA) with different ratios (0% to 100%) were prepared and the binding affinity for each mixture was evaluated (Table 1). In addition arachidonic, *cis*, 4,7,10,13,16,19-docosahexanoic, *cis*, 5,8,11,14,17,-eicosapentaenoic, linolenic, and γ - linolenic acids were evaluated. The results are shown in the Table 1. The mixture of LNA and PAM primarily showed selective inhibition of the specific binding of [^3H]-enkephalin to CHO-K1 cell membranes expressing human δ -opioid receptors at a concentration of 10 μM . The ratio of LNA: PAM (40:60) completely inhibited [^3H]-enkephalin from binding to the δ receptor (IC_{50} values of 22.0 μM).

ARA inhibited 65% of [^3H]-enkephalin binding to the human δ -opioid receptor (Table 1), and 80% specific binding of [^3H]-DAMGO to CHO-K1 cell membranes expressing human μ -opioid receptors at the concentration of 10 μM (Figure 2A), GLA inhibited 53% human μ -opioid receptors with IC_{50} and K_i values of 45.4 μM and 22.7 μM , respectively (Figure 2B).

The results are in accordance with those reported for lipid requirements on μ -opioid receptors binding affinity.¹⁴ Linoleic acid has also been reported as a noncompetitive inhibitor in some receptor binding assays.¹⁵ Moreover, it is well known that δ -opioid receptors could be palmitoylated, which might have a profound effect on the local conformation of this domain and possibly control interactions of GPCRs with specific regulatory proteins.¹⁶

The results of the binding to the human δ -opioid receptor in Table 1, shows an interesting relationship between the inhibition and the ratio of the fatty acids without statistically differences. The variations could be due to the competitive action of the fatty acids in the active site of the receptor, Hazegawa et al.¹⁴ recognized that even if, the lipids form a simple bilayer, some lipids could take different forms such as micelles, which could impact receptor recognition. Kanicky et al, related the interaction between monolayers of one or two fatty acids with their pK_a , which may affect surface concentration of the fatty acid mixture and, in turn, result in poor molecular packing. They found that unequal chain length and the saturated nature of the mixture of fatty acids leads to a disruption in molecular packing and a successive decrease in the pK_a values because of different intermolecular associations and/or interactions (Van der Waals, ion-dipole, etc).^{17, 18} The difference in the pK_a values could affect the binding of these fatty acids with the G-receptors. That is, the packing of the 2-fatty acids when in equal concentration might result in higher binding affinity than when one of the fatty acids is in greater concentration than the other fatty acid. Further studies are underway to evaluate this concept.

While the importance of the essential fatty acids is now recognized, additional studies that compare fatty acid profiles and their ratios need to be studied to understand their roles in the modulation of G-receptors.

To the best of our knowledge, this is the first time that a mixture of two fatty acids were evaluated for their binding affinity to human opioid receptors and that changing the ratio of the mixture of the two fatty acids provided a variety of selective δ -opioid receptor binding affinities. So far, the majority of clinically available opioid analgesics are μ agonists.¹⁹ However, μ agonists, such as morphine and its derivatives, have many side effects such as tolerance and dependency.²⁰ In order to meet the need for an efficacious analgesic without side effects, attention has focused on other opioid receptors such as κ and δ . Currently there are only a few agents that target δ receptors. Our findings provide interesting insights on new chemical scaffolds biosynthesized by nature that may lead to the discovery of potential new selective ligands for opioid receptors.

Acknowledgments

The project described was supported by Grant Number 5P20RR021929 from the National Center for Research Resources (NCRR) and 9P20GM104932 from the National Institute of General Medical Sciences, components of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Furthermore, this investigation was conducted in a facility constructed with support from research facilities improvement project C06 RR1450301 from the NIH National Center for Research Resources.

References

- Schroeder F, Petrescu AD, Huang H, Atshaves BP, McIntosh AL, Martin GG, Hostetler HA, Vespa A, Landrock D, Landrock K, Payne HR, Kier AD. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. *Lipids*. 2008; 43:1–17. [PubMed: 17882463]
- Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schioth HB. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. *Genomics*. 2006; 88:263–273. [PubMed: 16753280]
- Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. *Neuromol Med*. 2008; 10:219–235.
- Yehuda S. Polyunsaturated fatty acids as putative cognitive enhancers. *Med Hypotheses*. 2012; 79:456–461. [PubMed: 22800804]
- Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. *Curr Top Med Chem*. 2004; 4:1–17. [PubMed: 14754373]
- Stein C, Schafer M, Machelska H. Attacking pain at its source: new perspectives on opioids. *Nat Med*. 2003; 9:1003–1008. [PubMed: 12894165]
- Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. *Trends Pharmacol Sci*. 2011; 32:581–590. [PubMed: 21925742]
- Gao J, León F, Radwan MM, Dale OR, Gemelli CA, Manly SP, Lupien S, Wang X, Hill RA, Dugan FM, Cutler HG, Cutler SJ. Benzyl derivatives with in vitro binding affinity for human opioid receptors and cannabinoid receptors from the fungus *Eurotium repens*. *J Nat Prod*. 2011; 74:1636–1639. [PubMed: 21667972]
- White, TJ.; Bruns, T.; Lee, S.; Taylor, J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis, MA.; Gelfand, DH.; Sninsky, JJ.; White, TJ., editors. PCR protocols: A guide to methods and applications. Academic Press; San Diego: 1990.
- Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol*. 2011; 28:2731–2739. [PubMed: 21546353]
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*. 1976; 72:248–254. [PubMed: 942051]
- Gazis R, Rehner S, Chaverri P. Species delimitation in fungal endophyte diversity studies and its implications in ecological and biogeographic inferences. *Mol Ecol*. 2011; 20:3001–3013. [PubMed: 21557783]
- Ko TWK, Stephenson SL, Bahkali AH, Hyde KD. From morphology to molecular biology: can we use sequence data to identify fungal endophytes? *Fungal Div*. 2011; 50:113–120.
- Hasegawa JI, Loh HH, Lee NM. Lipid requirement for μ opioid receptor binding. *J Neurochem*. 1987; 49:1007–1012. [PubMed: 2887631]
- Ingkaninan K, Kunzel JKVFD, Ijzerman AP, Verpoorte R. Interference of linoleic acid fraction in some receptor binding assays. *J Nat Prod*. 1999; 62:912–914. [PubMed: 10395519]
- Petaja-Repo UE, Hogues M, Leskela TT, Markkanen PMH, Tuusa JT, Bouvier M. Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human δ opioid receptor. *J Biol Chem*. 2006; 281:15780–15789. [PubMed: 16595649]
- Kanicky JR, Shah DO. Effect of degree, type, and position of unsaturation on the pK_a of long-chain fatty acids. *J Coll Inter Sci*. 2002; 256:201–207.
- Kanicky JR, Shah DO. Effect of premicellar aggregation on the pK_a of fatty acid soap solutions. *Langmuir*. 2003; 19:2034–2038.
- Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. *Int Rev Psychiatry*. 2009; 21:143–151. [PubMed: 19367508]
- Benyamin R, Trescot AM, Datt S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. *Pain Physician*. 2008; 11:S105–S120. [PubMed: 18443635]

Figure 1.

Taxonomic data of strain UK-101 Morphological (a) verse and (b) reverse aspect of culture after 7 days on CYA at 7 days at 25 ± 2 °C; (c) ascomata, (d) asci and (e) ascospores; phylogenetic analysis of the fungus (in bold) and their nearest relatives as well as ^Tsequence of type and ^Rreference species (shown in grey box), the tree was constructed based on the rRNA gene sequences (ITS1-5.8S-ITS2) by using the maximum composite likelihood model; the tree was rooted with *Trametes versicolor* [AF042324] as an outgroup.

Figure 2.
IC₅₀ and K_i value of ARA (2A) and GLA (2B).

Binding affinity assay of the mixture of palmitic and linoleic acids, and different fatty acids for human opioid receptors (subtype δ , κ and μ).

Table 1

Sample	Opioid Receptors (%)			Binding affinity to δ opioid receptors (μ M)	
	δ	κ	μ	Ki	IC ₅₀
Active fraction, LNA:PAM (87:13)	98	15	-9	0.8	1.6
LNA:PAM (100:0)	15	15	-30	n.a. ^a	n.a
LNA:PAM (90:10)	76	28	-27	16.3	32.0
LNA:PAM (80:20)	51	14	1	4.7	9.4
LNA:PAM (70:30)	22	13	68	n.a	n.a
LNA:PAM (60:40)	63	25	-6	3.9	7.8
LNA:PAM (50:50)	103	15	-3	4.5	9.0
LNA:PAM (40:60)	107	26	-1	11.0	22.0
LNA:PAM (30:70)	87	23	10	12.5	25.0
LNA:PAM (20:80)	59	33	-5	6.5	13.0
LNA:PAM (10:90)	42	16	-13	n.a	n.a
LNA:PAM (0:100)	100	32	11	5.1	10.0
ARA	65	18	80	4.8	9.7
DHA	41	17	49	n.a	n.a
EPA	21	-6	47	n.a	n.a
ALA	23	10	37	n.a	n.a
GLA	39	-12	53	n.a	n.a
Naloxone	99	103	99	--	--

^aNot applicable